Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of ovarian cancer by stopping blood flow to the tumor.

PURPOSE: This randomized phase II trial is studying how well giving carboplatin together with thalidomide works compared to carboplatin alone in treating patients with ovarian epithelial cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Research UK
• Treatments: Carboplatin; Thalidomide

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed stage IC-IV ovarian epithelial cancer

• Post-menopausal OR

• Prior bilateral salpingo-oophorectomy and/or total abdominal hysterectomy

PATIENT CHARACTERISTICS:

Age:

• Over 18

Performance status:

• WHO 0-2

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

Other:

• No other concurrent invasive malignancies

• Not pregnant

• No diabetes mellitus

• No chronic neurological disease causing peripheral neuropathy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No other concurrent cytotoxic agents

Endocrine therapy:

• Not specified

Radiotherapy:

• Concurrent local radiotherapy for treatment of secondary disease sites allowed

Surgery:

• See Disease Characteristics